Trial intelligence / Profile preview

Fruquintinib plus bemarituzumab vs fruquintinib as third-line therapy in metastatic colorectal cancer

ChiCTR2600123864Phase 2Not yet recruiting

Sponsor

Tai'an City Central Hospital

Start

Apr 2026

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1